Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dimercaprol
Drug ID BADD_D00677
Description Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects.
Indications and Usage For the treatment of arsenic, gold and mercury poisoning. Indicated in acute lead poisoning when used concomitantly with edetate calcium disodium (DB00974).
Marketing Status approved
ATC Code V03AB09
DrugBank ID DB06782
KEGG ID D00167
MeSH ID D004112
PubChem ID 3080
TTD Drug ID Not Available
NDC Product Code 17478-526
UNII 0CPP32S55X
Synonyms Dimercaprol | 2,3-Dithiopropan-1-o1 | 2,3 Dithiopropan 1 o1 | British Anti-Lewisite Agent | Anti-Lewisite Agent, British | British Anti Lewisite Agent | 2,3-Dimercaptopropanol | 2,3 Dimercaptopropanol | British Anti-Lewisite | Anti-Lewisite, British | British Anti Lewisite | Dicaptol | Cadmium 2,3-Dimercaptopropanol | 2,3-Dimercaptopropanol, Cadmium | Cadmium 2,3 Dimercaptopropanol | BAL in Oil | Oil, BAL in | in Oil, BAL | B.A.L.
Chemical Information
Molecular Formula C3H8OS2
CAS Registry Number 59-52-9
SMILES C(C(CS)S)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abscess11.01.08.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Blepharospasm17.17.02.001; 06.05.01.001--Not Available
Blood pressure increased13.14.03.005--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Lacrimation increased06.08.02.004--
Muscle spasms15.05.03.004--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Oral discomfort07.05.05.001--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Paraesthesia17.02.06.005; 23.03.03.094--
Restlessness19.11.02.002; 17.02.05.021--
Rhinorrhoea22.12.03.021--
Salivary hypersecretion07.06.01.009--Not Available
Subcutaneous abscess23.11.04.008; 11.01.12.007--Not Available
Tachycardia02.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Vomiting07.01.07.003--
The 1th Page    1 2    Next   Last    Total 2 Pages